Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
Launched by BIOHAVEN THERAPEUTICS LTD. · May 14, 2024
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called BHV-7000 for people with Major Depressive Disorder (MDD). The goal is to see how well this treatment works and how safe it is for individuals experiencing moderate to severe depression. The study is currently looking for participants aged 18 to 75 who have been feeling depressed for at least two months and are willing to stop taking other medications for depression before joining the trial.
If you or someone you know is struggling with depression and meets the eligibility criteria, this trial could be an option. Participants will receive the treatment and will be closely monitored by the research team throughout the study. It's important to note that individuals with certain medical histories or currently taking multiple depression medications may not qualify. Overall, this trial aims to explore a new option for those who need help managing their depression.
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • 1. Subjects experiencing a moderate to severe episode of depression.
- • 2. Subjects experiencing a current episode of depression for at least 2 months.
- • 3. Subjects must be willing to discontinue all psychotropic medications (other medications to treat depression) before entering the study.
- • 4. Male and Female participants 18 to 75 years of age at the time of consent.
- • 5. Body Mass Index (BMI) must be ≥ 18 kg/m2 and ≤ 35 kg/m2.
- Key Exclusion Criteria:
- • 1. Subjects taking more than 2 medications (other than benzodiazepines and medications targeting insomnia) to treat depression at the screening visit.
- • 2. Subjects with a history of bipolar disorder, schizophrenia, or other neuropsychiatric conditions that may interfere with the conduct of the study.
- • 3. Subjects with a history of medical conditions that may interfere with the conduct of the study.
- • 4. Females who are pregnant, breastfeeding or planning to become pregnant.
About Biohaven Therapeutics Ltd.
Biohaven Therapeutics Ltd. is a biopharmaceutical company focused on developing innovative treatments for neurological and psychiatric disorders. With a commitment to addressing unmet medical needs, Biohaven leverages cutting-edge science and advanced drug development methodologies to create transformative therapies. The company's pipeline includes novel compounds aimed at improving the lives of patients suffering from conditions such as migraine, depression, and neurodegenerative diseases. Through rigorous clinical trials and a dedication to research excellence, Biohaven strives to deliver impactful solutions that enhance patient care and drive advancements in the field of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Redlands, California, United States
Media, Pennsylvania, United States
Toms River, New Jersey, United States
Rochester, New York, United States
Allentown, Pennsylvania, United States
Cedarhurst, New York, United States
Stanford, California, United States
Cherry Hill, New Jersey, United States
Dayton, Ohio, United States
Desoto, Texas, United States
New York, New York, United States
Flowood, Mississippi, United States
Chicago, Illinois, United States
Bellevue, Washington, United States
Oceanside, California, United States
Brooklyn, New York, United States
Boston, Massachusetts, United States
Colorado Springs, Colorado, United States
Orlando, Florida, United States
Mount Kisco, New York, United States
Jacksonville, Florida, United States
Orange, California, United States
Plano, Texas, United States
Farmington, Connecticut, United States
Wichita Falls, Texas, United States
New Orleans, Louisiana, United States
Anaheim, California, United States
Gaithersburg, Maryland, United States
North Charleston, South Carolina, United States
Watertown, Massachusetts, United States
Upland, California, United States
Boston, Massachusetts, United States
Dallas, Texas, United States
San Jose, California, United States
West Palm Beach, Florida, United States
Encino, California, United States
Naples, Florida, United States
Overland Park, Kansas, United States
Decatur, Georgia, United States
Savannah, Georgia, United States
Garden Grove, California, United States
New York, New York, United States
Saint Louis, Missouri, United States
Portland, Oregon, United States
Elgin, Illinois, United States
Rogers, Arkansas, United States
Phoenix, Arizona, United States
Las Vegas, Nevada, United States
Chandler, Arizona, United States
Little Rock, Arkansas, United States
Bellflower, California, United States
Garden Grove, California, United States
Los Angeles, California, United States
Riverside, California, United States
Miami Lakes, Florida, United States
Tampa, Florida, United States
Staten Island, New York, United States
Moosic, Pennsylvania, United States
Austin, Texas, United States
Dallas, Texas, United States
Houston, Texas, United States
Clinton, Utah, United States
Torrance, California, United States
Baltimore, Maryland, United States
Norwich, Connecticut, United States
Walnut Creek, California, United States
Little Rock, Arkansas, United States
Chino, California, United States
Farmington, Connecticut, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported